EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study

Masaki Hatano, Akira Okada, Yusuke Sasabuchi, Yuya Kimura, So Sato, Hisatoshi Ishikura, Takeyuki Tanaka, Taku Saito, Sakae Tanaka, Hideo Yasunaga

Osteoporosis International · 2026

DOI: 10.1007/s00198-026-08026-1 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Osteoporosis International, 2026. Verfasst von Masaki Hatano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan. h-masaki@g.ecc.u-tokyo.ac.jp. Hauptthemen laut MEDLINE: Teriparatide, Dementia, Bone Density Conservation Agents, Osteoporosis. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The University of Tokyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeriparatideDementiaBone Density Conservation AgentsOsteoporosisAntibodies, MonoclonalHumansFemaleAgedJapanMaleAged, 80 and overRisk AssessmentMiddle AgedIncidenceLongitudinal StudiesAlzheimer Disease

Stichwörter der Autor:innen

DementiaOsteoporosisRomosozumabTarget trial emulationTeriparatide

Substanzen

TeriparatideBone Density Conservation AgentsAntibodies, Monoclonalromosozumab

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan. h-masaki@g.ecc.u-tokyo.ac.jp.
  • Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Real-World Evidence, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
  • Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.

Förderung

  • The University of Tokyo

Zitieren

APA

Hatano, M., Okada, A., Sasabuchi, Y., Kimura, Y., Sato, S., Ishikura, H., Tanaka, T., Saito, T., Tanaka, S., & Yasunaga, H. (2026). Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study. Osteoporosis International. https://doi.org/10.1007/s00198-026-08026-1

Vancouver

Hatano M, Okada A, Sasabuchi Y, Kimura Y, Sato S, Ishikura H, et al. Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study. Osteoporosis International. 2026. doi:10.1007/s00198-026-08026-1

BibTeX
@article{Hatano2026,
  author = {Hatano, Masaki and Okada, Akira and Sasabuchi, Yusuke and Kimura, Yuya and Sato, So and Ishikura, Hisatoshi and Tanaka, Takeyuki and Saito, Taku and Tanaka, Sakae and Yasunaga, Hideo},
  title = {Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study},
  journal = {Osteoporosis International},
  year = {2026},
  doi = {10.1007/s00198-026-08026-1}
}
Kostenlos starten →